Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. - sprookjes - yvandenbroek - TriplyDB

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

http://www.wikidata.org/entity/Q31016954

about

Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10 Antibody vs. HIV in a clash of evolutionary titans Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection The HIV glycan shield as a target for broadly neutralizing antibodies Structural insights on the role of antibodies in HIV-1 vaccine and therapy A Blueprint for HIV Vaccine Discovery Antibody responses to envelope glycoproteins in HIV-1 infection HIV-1 neutralizing antibodies: understanding nature's pathways HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complex Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design Structure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications Role of a Putative gp41 Dimerization Domain in Human Immunodeficiency Virus Type 1 Membrane Fusion Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction Structural Characterization of HIV gp41 with the Membrane-proximal External Region Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies Structural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41 Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing Epitope Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies The good and evil of complement activation in HIV-1 infection Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India

P2860

Q21089590-A7544664-D4C0-4C7F-926D-24691EE6AFA8 Q24536059-572863C2-E2B4-4684-81EC-272C528807C6 Q24561905-B79C21A9-ADE5-4BDE-89F8-51DA59394002 Q24635002-BFA0D13F-341E-41A7-80D6-DB851D5F10C7 Q24655129-ABFCB53C-32BC-4C8D-9414-28C0AC27D1D7 Q26775082-B890F33A-1784-4635-94D8-32EB8403EC7C Q26786540-CBDF2E44-52CF-4A33-8BFA-E1A434C6D2A4 Q26829461-C99C18E1-81D4-47E7-969B-E2AEF7CAC8D8 Q26829865-16053223-F271-4030-A554-707B44C12F8F Q26991572-FE1D8B03-6AC3-4CD3-8FB5-E0327910619C Q27000480-E6FABCAE-0806-4A95-BA47-F2D5C0EEA0C5 Q27022055-EA89A6EC-4D78-4AB0-8692-19643637170B Q27489000-44C15B06-7C0C-4DDA-8BAA-6C752B647F58 Q27637675-2A708D06-E2C2-4149-AD7F-6BDA0FDFD1CC Q27644646-94E4AB64-0A6B-4FED-A5A4-173F1F0DC5A3 Q27653846-92706777-808E-48BC-97D8-2632931D3A1C Q27655865-65BEFF52-5861-46D8-9F01-FD2467C541C2 Q27657377-AE6A0D5E-8270-449D-A382-8734FB3C71C2 Q27657871-10BB5BC6-85DB-4AF1-9933-187CAA7377CF Q27661588-937B60B3-FC4E-4784-A7D2-AF388F4B6EE2 Q27662117-C5F316DB-6B70-461A-903F-AEE2E4EF32F5 Q27662155-73B97358-6563-47EE-974C-50FA5B66443C Q27665884-6AFA664C-B492-4B44-B948-F8709A16AEBA Q27665960-E5BE5EE5-3F8A-4D8A-BA9D-245BB00E8503 Q27670829-8C18CA37-D8E4-4F03-BEFF-241CB88CE725 Q27671696-F601762E-B95D-46D9-9755-218E649B68F5 Q27675131-34CB8435-EBF7-41F6-B0F9-D5F47F7AC686 Q27675260-24E02C84-414D-40A7-8302-195DD6F82A99 Q27676728-1172EFEA-5991-46DC-9D20-89CE903840E1 Q27676864-A5E97C41-70CD-4333-BB81-1F8B35556B5A Q27680125-51B3290F-1B34-4CB6-8795-19F260BE6620 Q27680872-4534B1B3-80D3-4603-95AC-F165247E3316 Q27681352-37622E1D-86D4-4A84-984E-A76B03D2BB6B Q27681501-11213B7A-140A-42A4-8F79-353B4A3155B0 Q27683553-8D332AE2-B250-49F4-A709-E71F6B20AA53 Q28066335-E46435A2-6B6A-47DB-8EB1-F40B9B765E55 Q28275986-B62A5553-A270-400D-8364-087DF3695A06 Q28469023-792B3EFB-9243-4B02-8DAC-89CA7F771BE4 Q28469283-7A2156A2-2F2B-4F89-8527-249AB1309A0E Q28483205-0E476875-01E3-4AC5-B1D2-452AA5B7B260

P2860

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

http://www.wikidata.org/entity/Q31016954

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.

@ast

Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.

@en

type

label

Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.

@ast

Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.

@en

prefLabel

Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.

@ast

Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.

@en

P1433

Q31016954-DD4D8F42-2F78-4E9F-A257-DAC93D2F7A01

P1476

Q31016954-C9EBC762-18B5-4F9B-9DFC-1787215D4646

P2093

Q31016954-0DCBC7E9-486C-4A75-A5A6-736E9E918796

Q31016954-2FBBECC5-A952-4105-8A70-28D99D8242DF

Q31016954-7AFD4F53-4422-40D6-B000-FD452EB0FC75

Q31016954-7FCADC93-C154-44B7-8031-AE82A43084F1

Q31016954-8C6E6521-2814-4B50-B6BE-9290338B4349

Q31016954-A9E9DF69-9F58-40FF-BAA7-048C3BE22C88

Q31016954-ABCCF94E-B2B2-4F31-B2A6-D9178940AE89

Q31016954-B5ABDB19-7AB0-41FA-A93D-0D752998E06D

Q31016954-E6A71B3A-F74F-4D34-8636-75719CEB24F9

P2860

Q31016954-00438F28-2860-40E5-8F72-1787758C3414

Q31016954-0281CD82-B0E7-482C-8EA7-10EA3DE9ACF8

Q31016954-07C0A191-5CE9-45DC-A87A-7D399E44D09C

Q31016954-0AB46F6C-1A3F-4B8A-8F78-6CC312ED963D

Q31016954-0F8B15FC-C382-458E-988E-D2CFAF4CA752

Q31016954-16504706-C27F-4355-BC3E-9F011BC0EB82

Q31016954-182423E3-8F91-4B58-9CB7-0973FB17D6C7

Q31016954-1F4E16A4-136F-4A7C-8476-CC81084709ED

Q31016954-21C2E2F4-C376-4F9B-8579-F7A29BFCB94E

Q31016954-23818346-6FC3-4D04-AC8D-48801448A213

P304

Q31016954-DDB0771C-7F85-47EC-AF2D-8C67EB813F53

P31

Q31016954-BF4B89EF-EB0D-4C42-B6AF-AA35C3FA2C19

P356

Q31016954-71003A65-6FED-4528-BB0F-7AC501C62EA0

P433

Q31016954-23AE7A63-CAD2-4B06-942A-37C008189278

P478

Q31016954-6F2AC5F7-7ADA-467F-8B85-64FECED2AC60

P50

Q31016954-11F7B182-DA60-4361-82A4-667AC493EEA3

Q31016954-36552558-17BE-45E3-8110-4BF6814D37B5

P577

Q31016954-C7875CBA-8081-4C60-B4DE-281F521186FC

P698

Q31016954-1A1D9CEA-4A1E-42C8-B61E-9B5F5FA89F9A

P921

Q31016954-BBF8BBAA-9763-492D-9FE9-512180559CF9

P932

Q31016954-439490A6-1CB3-4C65-ADBA-C1CA71511C98

P356

JVI.75.22.10892-10905.2001

P1433

Journal of Virology

P1476

Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.

@en

P2093

A F Labrijn

http://www.w3.org/2001/XMLSchema#string

C Spenlehauer

http://www.w3.org/2001/XMLSchema#string

D R Burton

http://www.w3.org/2001/XMLSchema#string

G Stiegler

http://www.w3.org/2001/XMLSchema#string

H Katinger

http://www.w3.org/2001/XMLSchema#string

J M Binley

http://www.w3.org/2001/XMLSchema#string

J P Moore

http://www.w3.org/2001/XMLSchema#string

M B Zwick

http://www.w3.org/2001/XMLSchema#string

M Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1

Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors

Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

Core structure of gp41 from the HIV envelope glycoprotein

Atomic structure of the ectodomain from HIV-1 gp41

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

P304

10892-10905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.75.22.10892-10905.2001

http://www.w3.org/2001/XMLSchema#string

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Erica Ollmann Saphire

Paul Whi Parren

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11602729

http://www.w3.org/2001/XMLSchema#string

P921

P932

114669

http://www.w3.org/2001/XMLSchema#string